Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 7, 2007, Pages 1023-1030

  Ricci, Sergio ^a   Boni, Giuseppe ^b   Pastina, Ilaria ^a   Genovesi, Dario ^b   Cianci, Claudia ^a   Chiacchio, Serena ^b,d   Orlandini, Cinzia ^a   Grosso, Mariano ^b   AlSharif, Abedallatif ^b,e   Chioni, Aldo ^a   Di Donato, Samantha ^a   Francesca, Francesco ^a   Selli, Cesare ^b   Rubello, Domenico ^c   Mariani, Giuliano ^b  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c S MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^d INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^e JORDAN UNIVERSITY HOSPITAL   (Jordan)

Author keywords

153Sm EDTMP; Chemotherapy; Clinical benefit; Combination therapy; Hormone refractory prostate cancer

Indexed keywords

ESTRAMUSTINE PHOSPHATE; LEXIDRONAM SAMARIUM SM 153; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANEMIA; ARTICLE; BONE METASTASIS; BONE PAIN; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; DRUG RESPONSE; FEMALE; HUMAN; LEUKOPENIA; MALE; PAIN ASSESSMENT; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BONE NEOPLASMS; DRUG COMBINATIONS; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PAIN; PALLIATIVE CARE; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 34250368094     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0343-8     Document Type: Article

References (38)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. McRea LE, Karafin L. Carcinoma of the prostate: metastases, therapy, and survival-A statistical analysis of 500 cases. Int Coll Surg J 1958;29:723-8.
3. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756-64.
4. Sabbatini P, Larson SM, Kremer A, Zhang ZF, Sun M, Yeung H, et al. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol 1999;17:948-57.
5. Carroll PR, Kantoff PW, Balk SP, Brown MA, D'amico AV, George DJ, et al. Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology 2002;60 suppl 1:1-6.
6. Chodak GW, Keane T, Klotz L. Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology 2002;60:201-8.
7. Tannock IF. Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? J Clin Oncol 1985;3:1013-21.
8. Eisenberger MA, Simon R, O'Dwyer PJ, Wittes RE, Friedman MA. A reevaluation of nonhormonal cytotoxic chemotherapy in treatment of prostatic carcinoma. J Clin Oncol 1985;3:827-41.
9. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
10. Petrylak DP, Tangen CM, Hussain MHA, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20.
11. Serafini AN. Therapy of metastic bone pain. J Nucl Med 2001;42:895-906.
12. Lewington VJ. Bone-seeking radionuclides for therapy. J Nucl Med 2005;46:38S-47S.
13. Pandit-Taskar N, Batraki M, Divgi R. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med 2004;45:1358-65.
14. Dafermou A, Colamussi P, Giganti M, Cittanti C, Bestagno M, Piffanelli A. A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur J Nucl Med 2001;28:788-98.
15. Serafini AN. Systemic metabolic radiotherapy with samarium-153-EDTMP for the treatment of painful bone metastasis. Quart J Nucl Med 2001;45:91-9.
16. Serafini AN. Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastasis. Cancer 2000;88 suppl:2934-9.
17. Serafini AN, Houston SJ, Resche I, Quick DP, Grund FM, Ell PJ, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double blind placebo-controlled clinical trial. J Clin Oncol 1998;16:1574-81.
18. Sartor O, Reid R, Hoskin PJ, Quick DP, Ell PJ, Coleman RE, et al. Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004;63:940-5.
19. Resche I, Chatal JF, Pecking A, Ell P, Duchesne G, Rubens R, et al. A dose-controlled study of Sm-153-EDTMP in the treatment of patients with painful bone metastasis. Eur J Cancer 1997;33:1583-91.
20. 153Sm-EDTMP therapy includes pain palliation and lesion regression/stabilization (abstract). Eur J Nucl Med 2001;28:1198.
21. 153Sm-EDTMP in bone metastasis from different cancers (abstract). Eur J Nucl Med 2001;28:1054.
22. Akerley W, Butera J, Wehbe T, Noto R, Stein B, Safran H, et al. A multiinstitutional, concurrent chemoradiation trial of strontium-89 extramustine and vinblastine for hormone refractory prostate carcinoma involving bone. Cancer 2002;94:1654-60.
23. 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med 2002;43:79-86.
24. Pagliaro LC, Delpassand ES, Williams D, Millikan RE, Tu SM, Logothetis CJ. A phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases. Cancer 2003;12:2988-94.
25. Logothetis C, Tu S, Navone N. Targeting prostate cancer bone metastases. Cancer 2003;97:785-8.
26. Valdés Olmos RA, Hoefnagel CA. Radionuclide therapy in oncology: the dawning of its concomitant use with other modalities? Eur J Nucl Med Mol Imaging 2004;31:929-31.
27. Tu S, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, et al. Bone-targeted therapy for advanced androgen independent carcinoma of the prostate: a randomised phase II trial. Lancet 2001;367:336-41
28. Palmedo H, Manka-Waluch A, Albers P, Schmidt-Wolf IG, Reinhardt M, Ezziddin S, et al. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidene-diphosphonate. J Clin Oncol 2003;21:2869-75.
29. Palmedo H, Bucerius J. Radionuclide therapy in oncology: repeated administrations of high dose rate radiopharmaceuticals (abstract). Eur J Nucl Med Mol Imaging 2004;31:1556.
30. Anderson P. Samarium for osteoblastic bone metastases and osteosarcoma. Expert Opin Pharmacother 2006;7:1475-86.
31. Anderson PM, Wiseman GA, Erlandson L, Rodriguez V, Trotz B, Dubansky SA, et al. Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma. Clin Cancer Res 2005;11:6895-900.
32. 153samarium-EDTMP and melphalan as a conditioning regimen for secondary acute myelogenous leukemia. Pediatr Transplantation 2005;9:122-6.
33. Knop S, Dohmer BM, Kanz L, Bares R, Einsele H. 153 Samarium-EDTMP in myeloablative dosage followed by a second autotransplantation in patients with relapsed multiple myeloma (abstract). Haematologica 2004;89:ECR36.
34. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7.
35. Berry S, Waldron T, Winquist E, Lukka H. The use of bisphosphonates in men with hormone-refractory prostate cancer: a systematic review of randomized trials. Can J Urol 2006;13:3180-8.
36. Storto G, Klain M, Paone G, Liuzzi R, Molino L, Marinelli A, et al. Combined therapy with Sr-89 and zoledronic acid in patients with painful bone metastases. Bone 2006;39:35-41.
37. Laplanche A, Beuzeboc P, Lumbroso J, Di Palma M, Theodore C, Prapotnich D, et al. A phase II trial of docetaxel and samarium in patients with bone metastases from castration-refractory prostate cancer (CRPC) and a response or stabilization after induction docetaxel-estramustine (abstract). Proc Am Soc Clin Oncol 2006;24:4608.
38. Widmark A, Linne T, Modig H, Johansson L. Optimizing the time of co-administration of docetaxel and samarium-153 for advanced androgen independent carcinoma of the prostate (abstract). Proc Am Soc Clin Oncol 2003;22:433.